Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

 

  Initiated both dosing regimens of the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide  

 

  Dosing ongoing for Phase 1 monotherapy study of NUV-868  

 

  Nominated undisclosed Drug-Drug Conjugate (DDC) as first clinical candidate; expect to submit an IND by year end 2023  

 

  Strong balance sheet with cash, cash equivalents and marketable securities of $661.0 million as of December 31, 2022  

 

 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

 

"In the fourth quarter, we dosed the first patient in both dosing regimens of our Phase 1b study of NUV-868 in combination with olaparib or enzalutamide. This milestone sustains the program's strong momentum, which we expect to continue in 2023. As we advance the Phase 1 monotherapy and combination studies of NUV-868, we look forward to more deeply understanding how this therapy may be able to improve the lives of patients with advanced solid tumors," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "We also expect to submit an IND for the first clinical candidate from our DDC platform by the end of the year."

 

  Recent Business Updates  

 

  NUV-868, BD2-Selective BETi : Advanced solid tumors  

 
  •   Dosed the first patient in both dosing regimens of the Phase 1b combination study . In December 2022, Nuvation Bio initiated a Phase 1b study of NUV-868 in combination with olaparib in patients with ovarian cancer, pancreatic cancer, metastatic castration-resistant prostate cancer (mCRPC), triple negative breast cancer, and other solid tumors, and in combination with enzalutamide in patients with mCRPC.
  •  
  •   Dosing underway in the Phase 1 monotherapy study. The Company continues to enroll the Phase 1 monotherapy study in advanced solid tumors.
  •  

  Drug-Drug Conjugate Platform:   Solid tumors  

 
  •   Nominated first clinical candidate. Nuvation Bio expects to submit an Investigational New Drug (IND) application for an undisclosed DDC candidate with the U.S. Food and Drug Administration by year end 2023.
  •  

  Fourth Quarter and Full Year 2022 Financial Results  

 

As of December 31, 2022, Nuvation Bio had cash, cash equivalents and marketable securities of $661.0 million.

 

For the three months ended December 31, 2022, research and development expenses were $16.9 million, compared to $22.0 million for the three months ended December 31, 2021. The decrease was primarily due to a $3.7 million decrease in third-party costs related to research services and manufacturing, as well as a $1.5 million decrease in personnel-related costs driven by the termination of the NUV-422 program offset by a $0.1 million increase in miscellaneous expenses. Research and development expenses for the year ended December 31, 2022 were $87.8 million compared to $69.0 million for the year ended December 31, 2021.

 

For the three months ended December 31, 2022, general and administrative expenses were $7.4 million, compared to $7.6 million for the three months ended December 31, 2021. The decrease was primarily due to a $0.4 million decrease in legal fees, a $0.2 million decrease in professional fees, and a $0.2 million decrease in miscellaneous expenses offset by a $0.5 million increase in personnel-related costs driven by an increase in headcount and stock-based compensation and a $0.1 million increase in taxes. General and administrative expenses for the year ended December 31, 2022 were $31.9 million compared to $24.3 million for the year ended December 31, 2021.

 

For the three months ended December 31, 2022, Nuvation Bio reported a net loss of $20.8 million, or $(0.10) per share. This compares to a net loss of $25.1 million, or $(0.12) per share, for the comparable period in 2021. Net loss for the year ended December 31, 2022 was $104.2 million compared to $86.8 million for the year ended December 31, 2021.

 

  About Nuvation Bio  

 

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com .

 

  Forward Looking Statements  

 

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential therapeutic benefit of Nuvation Bio's product candidates, the expected continued momentum of Nuvation Bio's clinical trials and the expected timing of an IND filing for Nuvation Bio's first nominated DDC clinical candidate. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Annual Report on Form 10-K filed on March 15, 2023, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

 
                                                                                                                                                                                                 
  Nuvation Bio Inc. and Subsidiaries     
    
  Consolidated Balance Sheets     
(In thousands, except share and per share data)   December 31,  
  

 

 
 

  2022  

 
  

 

 
 

  2021  

 
    
  Assets     
Current assets:    
Cash and cash equivalents  

$

 
 

101,099

 
  

$

 
 

132,423

 
Prepaid expenses  

 

 
 

3,819

 
  

 

 
 

3,642

 
Marketable securities available-for-sale, at fair value  

 

 
 

559,915

 
  

 

 
 

632,969

 
Interest receivable on marketable securities  

 

 
 

2,485

 
  

 

 
 

3,039

 
Total current assets  

 

 
 

667,318

 
  

 

 
 

772,073

 
Property and equipment, net  

 

 
 

894

 
  

 

 
 

786

 
Lease security deposit  

 

 
 

138

 
  

 

 
 

421

 
Operating lease right-of-use assets  

 

 
 

3,791

 
  

 

 
 

2,871

 
Total assets  

$

 
 

672,141

 
  

$

 
 

776,151

 
    
  Liabilities and stockholders' equity    
Current liabilities:    
Accounts payable  

$

 
 

2,139

 
  

$

 
 

3,925

 
Current operating lease liabilities  

 

 
 

1,206

 
  

 

 
 

863

 
Accrued expenses  

 

 
 

9,816

 
  

 

 
 

12,137

 
Total current liabilities  

 

 
 

13,161

 
  

 

 
 

16,925

 
Warrant liability  

 

 
 

850

 
  

 

 
 

11,037

 
Non-current operating lease liabilities  

 

 
 

3,054

 
  

 

 
 

2,192

 
Total liabilities  

 

 
 

17,065

 
  

 

 
 

30,154

 
    
Stockholders' equity    
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share;    
1,060,000,000 shares authorized as of December 31, 2022 (Class A 1,000,000,000, Class B 60,000,000)    
and December 31, 2021, respectively; 218,632,699 (Class A 217,632,699, Class B 1,000,000) and 149,042,155 (Class A 91,397,142,    
217,948,568 (Class A 216,948,568, Class B 1,000,000) issued and outstanding as of December 31, 2022    
and 2021, respectively  

 

 
 

927,604

 
  

 

 
 

909,985

 
Accumulated deficit  

 

 
 

(267,002)

 
  

 

 
 

(162,803)

 
Accumulated other comprehensive income  

 

 
 

(5,526)

 
  

 

 
 

(1,185)

 
Total stockholders' equity  

 

 
 

655,076

 
  

 

 
 

745,997

 
Total liabilities and stockholders' equity  

$

 
 

672,141

 
  

$

 
 

776,151

 
 
                                                                                                                                                                                                                                                                                                                            
  Nuvation Bio Inc. and Subsidiaries         
        
  Consolidated Statements of Operations and Comprehensive Loss         
(In thousands, except per share data)        
   Three Months Ended December 31,     Years Ended December 31,  
  

 

 
 

  2022  

 
  

 

 
 

  2021  

 
  

 

 
 

  2022  

 
  

 

 
 

  2021  

 
  Operating expenses:         
Research and development  

$

 
 

16,871

 
  

$

 
 

22,002

 
  

$

 
 

87,815

 
  

$

 
 

69,037

 
General and administrative  

 

 
 

7,464

 
  

 

 
 

7,607

 
  

 

 
 

31,919

 
  

 

 
 

24,281

 
  Total operating expenses   

 

 
 

24,335

 
  

 

 
 

29,609

 
  

 

 
 

119,734

 
  

 

 
 

93,318

 
        
  Loss from operations   

 

 
 

(24,335)

 
  

 

 
 

(29,609)

 
  

 

 
 

(119,734)

 
  

 

 
 

(93,318)

 
  Other income (expense):         
Interest income  

 

 
 

3,523

 
  

 

 
 

902

 
  

 

 
 

7,448

 
  

 

 
 

2,963

 
Investment advisory fees  

 

 
 

(225)

 
  

 

 
 

(190)

 
  

 

 
 

(872)

 
  

 

 
 

(644)

 
Change in fair value of warrant liability  

 

 
 

321

 
  

 

 
 

3,899

 
  

 

 
 

10,187

 
  

 

 
 

4,231

 
Net loss on marketable securities  

 

 
 

(129)

 
  

 

 
 

(136)

 
  

 

 
 

(1,228)

 
  

 

 
 

(80)

 
  Total other income (expense), net   

 

 
 

3,490

 
  

 

 
 

4,475

 
  

 

 
 

15,535

 
  

 

 
 

6,470

 
        
  Loss before income taxes   

 

 
 

(20,845)

 
  

 

 
 

(25,134)

 
  

 

 
 

(104,199)

 
  

 

 
 

(86,848)

 
Provision for income taxes  

 

 
 

—

 
  

 

 
 

—

 
  

 

 
 

—

 
  

 

 
 

—

 
  Net loss   

$

 
 

(20,845)

 
  

$

 
 

(25,134)

 
  

$

 
 

(104,199)

 
  

$

 
 

(86,848)

 
        
Net loss per share attributable to common stockholders, basic and diluted  

$

 
 

(0.10)

 
  

$

 
 

(0.12)

 
  

$

 
 

(0.48)

 
  

$

 
 

(0.44)

 
Weighted average common shares outstanding, basic and diluted  

 

 
 

218,497

 
  

 

 
 

210,224

 
  

 

 
 

216,721

 
  

 

 
 

197,887

 
        
  Comprehensive loss:         
Net loss  

$

 
 

(20,845)

 
  

$

 
 

(25,134)

 
  

$

 
 

(104,199)

 
  

$

 
 

(86,848)

 
Other comprehensive income (loss), net of taxes:        
Unrealized gain (loss) on available-for-sale securities, net  

 

 
 

2,591

 
  

 

 
 

(1,573)

 
  

 

 
 

(4,341)

 
  

 

 
 

(2,742)

 
  Comprehensive loss   

$

 
 

(18,254)

 
  

$

 
 

(26,707)

 
  

$

 
 

(108,540)

 
  

$

 
 

(89,590)

 
 

 

 

  

  

  Nuvation Bio Investor Contact:  
ir@nuvationbio.com  

 

  Nuvation Bio Media Contact:  
nuvation@argotpartners.com  

 

News Provided by Business Wire via QuoteMedia

NUVB
The Conversation (0)
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

 

 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors.

 

"We are delighted to have Dr. Mashal join our Board of Directors," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Robert is a seasoned biotech industry veteran and his experience as an investor, operator, and medical oncologist will provide us with valuable insights. We look forward to working with Robert to advance Nuvation's pipeline."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

 

  NUV-1511 is the first clinical candidate from the company's novel drug-drug conjugate platform  

 

  Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

 

  Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing  

 

  Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

 

  Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide  

 

  Enrollment ongoing in the Phase 1 monotherapy study of NUV-868  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

 

  Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development  

 

 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the formation of a Scientific Advisory Board. The Scientific Advisory Board will work alongside the Nuvation Bio management team to advance its pipeline of therapeutic candidates for some of the most difficult-to-treat cancers.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Option Plan.

Contact:
David Regan, CEO
+1-902-536-1932
david@sonanano.com

Keep reading...Show less
Sona Nanotech

Sona Nanotech


Keep reading...Show less
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

 

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024.

 

Details for the Company's presentation:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

 

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84 th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

 

The presentations are:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

 
  •    Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb   
  •  
  •    CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk of death by 50%   
  •  
  •    FDA has given CEL-SCI the go-ahead to commence a confirmatory Registration Study for Multikine for the target population in head and neck cancer   
  •  
  •    Dr. Selvaggi will be supporting CEL-SCI to bring Multikine to patients through a confirmatory registrational path that has been agreed with regulatory authorities and that has a potential for cure   
  •  

  CEL-SCI Corporation   (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor. Dr. Selvaggi joins CEL-SCI as the Company recently received its go-ahead from the U.S. Food and Drug Administration (FDA) for its confirmatory Registration Study of Multikine* in the treatment of head and neck cancer.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606671425/en/  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

 

  VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice  

 

  Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone  

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×